Clinical trials: HNPCC
Lynch Syndrome, Hereditary Nonpolyposis Colorectal Cancer
Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch Syndrome
Lynch syndrome (LS) is an autosomal dominant hereditary condition that markedly increases the risk of colorectal cancer (CRC) and other malignancies.
- Conditions
- Lynch Syndrome, Hereditary Nonpolyposis Colorectal Cancer, HNPCC, Colorectal Cancer (CRC)
- Trial name
- BioLynch (NCT07838246)
- Testing
- Study procedures
- Where
- Italy
- Volunteers
- 109 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas
- Trial name
- NCT05692596
- Testing
- Data collection
- Where
- United States
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lynch Syndrome
Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers
The primary objective is to assess the effect of vaccination with neopeptide-loaded dendritic cells on disease-free survival (DFS) compared to placebo in LS subjects who are known to be carrier of a germline MMR-gene mutation…
- Trial name
- PROTECT-Lynch (NCT07609901)
- Testing
- Arm A: DC vaccination
- Where
- Netherlands
- Volunteers
- 372 people
- Sponsor
- Radboud University Medical Center
Lynch Syndrome, Recurrent Endometrial Carcinoma
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent).
- Conditions
- Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma
- Trial name
- NCT04906382
- Testing
- Biopsy, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Floor Backes, MD
Breast Cancer Risk, Ovarian Cancer Risk
Population Based Germline Testing for Early Detection and Prevention of Cancer
PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and/or womb cancer.
- Conditions
- Breast Cancer Risk, Ovarian Cancer Risk, Cancer Gene Mutation
- Trial name
- PROTECT-C (NCT07498829)
- Testing
- Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk
- Where
- United Kingdom
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Ileal Pouch-Anal Anastomosis
Ileal Pouch-Anal Anastomosis Registry
Little is known about the factors that predispose patients to complications after an ileal pouch-anal anastomosis procedure (IPAA).
- Trial name
- IPAA (NCT01026480)
- Where
- United States
- Volunteers
- 936 people
- Sponsor
- Boston Medical Center
Colorectal Cancer, Hereditary Non-polyposis Colon Cancer
Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
RATIONALE: The use of a CD-ROM may help patients with colorectal cancer or a family history of colorectal cancer make informed decisions about undergoing microsatellite instability (MSI) testing.
- Trial name
- NCT00450424
- Testing
- counseling intervention, CD-ROM intervention
- Where
- 3 sites in United States
- Volunteers
- 239 people
- Sponsor
- Fox Chase Cancer Center